Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona M Blows

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Breast Cancer Research : BCR|November 25, 2011
Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significanceH Raza Ali, Sarah-Jane Dawson, Fiona M Blows, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2010
Molecular pathology in epidemiologic studies: a primer on key considerationsMark E Sherman, Will Howatt, Fiona M Blows, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 13, 2015
Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue MicroarraysFiona M Blows, Hamid R Ali, Sarah-J Dawson, et al.
The Journal of Pathology|September 29, 2011
A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancerH Raza Ali, Sarah-Jane Dawson, Fiona M Blows, et al.
BJC Reports|November 8, 2024
Expression of transglutaminase-2 (TGM2) in the prognosis of female invasive breast cancerFiona M Blows, H Raza Ali, Wei Cope, et al.
BMC Cancer|December 5, 2014
Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancerGordon C Wishart, Emad Rakha, Andrew Green, et al.
Breast Cancer Research and Treatment|December 3, 2013
Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expressionHisani N Horne, Mark E Sherman, Montserrat Garcia-Closas, et al.
British Journal of Cancer|December 19, 2015
Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markersHyuna Sung, Montserrat Garcia-Closas, Jenny Chang-Claude, et al.
Plos Medicine|June 4, 2010
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesFiona M Blows, Kristy E Driver, Marjanka K Schmidt, et al.
Genome Medicine|May 8, 2026
The contribution of rare germline variants to the immune landscape of breast cancerFelipe Rojas-Rodríguez, Sander Canisius, Renske Keeman, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Breast Cancer Research : BCR|November 25, 2011
Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significanceH Raza Ali, Sarah-Jane Dawson, Fiona M Blows, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2010
Molecular pathology in epidemiologic studies: a primer on key considerationsMark E Sherman, Will Howatt, Fiona M Blows, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 13, 2015
Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue MicroarraysFiona M Blows, Hamid R Ali, Sarah-J Dawson, et al.
The Journal of Pathology|September 29, 2011
A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancerH Raza Ali, Sarah-Jane Dawson, Fiona M Blows, et al.
BJC Reports|November 8, 2024
Expression of transglutaminase-2 (TGM2) in the prognosis of female invasive breast cancerFiona M Blows, H Raza Ali, Wei Cope, et al.
BMC Cancer|December 5, 2014
Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancerGordon C Wishart, Emad Rakha, Andrew Green, et al.
Breast Cancer Research and Treatment|December 3, 2013
Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expressionHisani N Horne, Mark E Sherman, Montserrat Garcia-Closas, et al.
British Journal of Cancer|December 19, 2015
Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markersHyuna Sung, Montserrat Garcia-Closas, Jenny Chang-Claude, et al.
Plos Medicine|June 4, 2010
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesFiona M Blows, Kristy E Driver, Marjanka K Schmidt, et al.
Genome Medicine|May 8, 2026
The contribution of rare germline variants to the immune landscape of breast cancerFelipe Rojas-Rodríguez, Sander Canisius, Renske Keeman, et al.
Pageof 2